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Abstract
Objective: The assessment of the quality of life in patients with lung cancer has become one of the main goals 
in current clinical trials. To assess the quality of life of these patients, the most widely used instrument is the 
30-item European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC 
QLQ-C30) in conjunction with its supplemental 13-item lung cancer-specific module (QLQ-LC13). The objective of 
this study was to assess the reproducibility of the Brazilian Portuguese version of these questionnaires. Methods: A 
prospective study involving 30 stable outpatients with lung cancer who completed the instruments on the first day 
of the study and two weeks later. Results: The test-retest reproducibility using the intraclass correlation coefficient 
for the EORTC QLQ-C30 and the QLQ-LC13 ranged from 0.64 to 1.00 and from 0.64 to 0.95, respectively. 
No correlations were found between the domains of the instruments and clinical parameters. Conclusions: Our 
findings show that these instruments were reproducible in this sample of patients with lung cancer in Brazil.
Keywords: Lung neoplasms; Reproducibility of results; Quality of life.
Resumo
Objetivo: A avaliação da qualidade de vida em pacientes com câncer de pulmão tem se tornado um dos principais 
objetivos em ensaios clínicos atuais. Para avaliar a qualidade de vida desses pacientes, o instrumento mais utilizado 
é o 36-item European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire 
(EORTC QLQ-C30) em conjunto com seu módulo específico para câncer de pulmão com 13 itens (QLQ-LC13). 
O objetivo deste estudo foi avaliar a reprodutibilidade da versão em português do Brasil desses questionários. 
Métodos: Estudo prospectivo com 30 pacientes ambulatoriais estáveis com câncer de pulmão, os quais completaram 
os instrumentos no primeiro dia do estudo e duas semanas depois. Resultados: A reprodutibilidade teste-reteste 
através do coeficiente de correlação intraclasse para o EORTC QLQ-C30 e o QLQ-LC13 variou de 0,64 a 1,00 e 
de 0,64 a 0,95, respectivamente. Não houve correlações entre os domínios dos instrumentos e os parâmetros 
clínicos. Conclusões: Estes achados demonstram a reprodutibilidade dos instrumentos utilizados nesta amostra de 
pacientes com câncer de pulmão no Brasil.
Descritores: Câncer de pulmão; Reprodutibilidade dos testes; Qualidade de vida.
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of this study was to assess the reproducibility 
of the Brazilian Portuguese-language version 
of the EORTC QLQ-C30 in conjunction with the 
QLQ-LC13 in a sample of patients with lung 
cancer.
Methods
This was a prospective observational study 
involving 30 patients diagnosed with lung 
cancer and under treatment at the Oncology/
Pulmonology Outpatient Clinic of the Federal 
University of São Paulo/Paulista School of 
Medicine, in the city of São Paulo, Brazil. The 
inclusion criteria were as follows: a definite 
cytological or histological diagnosis of lung 
cancer; clinical stability (no changes in the 
symptoms of cough, expectoration, or dyspnea—
these to have been registered on a structured 
form for outpatient follow-up, together 
with an affirmation that there had been no 
hospitalizations or changes in the treatment 
regimen in the 10 days preceding the interview); 
and a score equal to or greater than 21 on the 
Mini-Mental State Examination (MMSE).(8) The 
study was approved by the local research ethics 
committee, and all participants gave written 
informed consent.
In the first visit, the patients underwent 
clinical evaluation, using a structured form 
especially designed for patients with lung 
cancer, and completed the MMSE (Figure 1). The 
following independent variables were assessed: 
gender; age; smoking history and tobacco 
intake; histological type (adenocarcinoma, 
squamous cell carcinoma, small cell carcinoma, 
or other);(9) staging (in accordance with the 1997 
tumor-node-metastasis classification, based on 
which patients with non-small cell lung cancer 
were classified as having stage IA, IB, IIA, IIB, 
IIIA, IIIB, or IV disease);(10) Karnofsky scale 
score;(4) spirometry results (FEV1 and FVC in 
percentage of predicted, as well as the FEV1/FVC 
ratio in percentage;(11) MMSE score; and EORTC 
QLQ-C30 and QLQ-LC13 scores.(12)
In both visits, the Karnofsky scale was 
administered before the questionnaires.(4)
Spirometry was performed at the end of the 
first interview, in accordance with the Brazilian 
Thoracic Association guidelines.(11)
The test-retest reproducibility of the EORTC 
QLQ-C30+QLQ-LC13 was determined after the 
questionnaire was administered twice, 15 days 
Introduction
Worldwide, lung cancer is one of the most 
common types of neoplasia, and, despite recent 
advances, its prognosis remains poor, with an 
overall five-year survival rate of less than 15%.(1) 
In Brazil, the number of new cases of lung cancer 
estimated for 2010 is 17,800 among men and 
9,930 among women. These values correspond 
to an estimated incidence of 18 new cases per 
100,000 men and 10 new cases per 100,000 
women.(2)
In the past, studies of patients with lung 
cancer focused on traditional outcomes, such as 
survival, disease-free intervals, or local control. 
However, due to the high morbidity and mortality 
of this disease, the inclusion of instruments to 
assess quality of life as an outcome measure has 
become extremely important.(3)
The Karnofsky scale(4) and the Eastern 
Cooperative Oncology Group (ECOG) scale,(5) 
which are widely used for assessing the physical 
performance of patients, are based only on 
observation by health professionals and do not 
take into account the views of the patients 
themselves. In contrast, the assessment of quality 
of life using generic or specific questionnaires 
provides information not only about physical 
issues but also about psychosocial, functional, 
and spiritual aspects, and more importantly, 
from the perspective of the patient. The 
30-item European Organization for Research 
and Treatment of Cancer Core Quality of Life 
Questionnaire (EORTC QLQ-C30)—in conjunction 
with its supplemental 13-item lung cancer-
specific module (QLQ-LC13)—was specifically 
designed to assess the quality of life of patients 
with lung cancer and, worldwide, it is the most 
widely used instrument in clinical trials. This 
questionnaire has appropriate psychometric 
properties, and its reproducibility and validity 
have been demonstrated in various languages 
and cultures. In addition, the score on the 
global scale (EORTC QLQ-C30) is considered to 
be a predictor of survival in patients with lung 
cancer.(6) Although this questionnaire is used 
in international multicenter studies involving 
facilities in Brazil, there have been no studies 
assessing the reproducibility of the Brazilian 
Portuguese-language version of this instrument. 
The use of reproducible questionnaires is 
essential, since it increases their internal validity 
in individual studies.(7) Therefore, the objective 
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The patients completed the questionnaire by 
reading the questions along with the researcher, 
as recommended in the accompanying manual. 
The environment was quiet, and interruptions 
were not allowed during the administration of 
apart, by the same researcher (Figure 1). In 
addition, the mean scores obtained on the various 
scales of the questionnaire were compared with 
the reference values established by the research 
group on quality of life of the EORTC, based 
on the minimum clinically significant difference, 
which, for this instrument, ranges from 5 to 
10 points,(13,14) and comparisons with other 
reproducibility studies of other language versions 
of this instrument were performed.(1,15-20)
The protocol used the Brazilian 
Portuguese-language version of the EORTC 
QLQ-C30+QLQ-LC13 provided by the research 
group on quality of life of the EORTC, responsible 
for the development of the questionnaire, 
and followed the methods used for assessing 
reproducibility and for cross-cultural adaptation 
of other instruments in Brazil.(7,21-23)
The general questionnaire (EORTC QLQ-C30) 
comprises 30 questions related to five functional 
scales (physical functioning, role functioning, 
emotional functioning, social functioning, and 
cognitive functioning), a global health and 
quality of life scale, three symptom scales (fatigue, 
pain, and nausea/vomiting), and six single 
items regarding additional symptoms (dyspnea, 
insomnia, appetite loss, constipation, diarrhea, 
and financial difficulties). The QLQ-LC13, which 
is supplemental to the EORTC QLQ-C30, is a 
lung cancer-specific module comprising 13 
questions related to a symptom scale (dyspnea) 
and nine single items regarding symptoms and 
adverse effects of treatment (cough, hemoptysis, 
mucositis, dysphagia, peripheral neuropathy, 
alopecia, chest pain, arm/shoulder pain, and 
pain elsewhere).(1,6) Points are scored according 
to the responses chosen by the patient. The 
options allowed by the questionnaire are “não” 
(“not at all”; one point), “pouco” (“a little”; two 
points), “moderadamente” (“quite a bit”; three 
points), or “muito” (“very much”; four points). 
In the two questions related to the global health 
and quality of life scale, the options to choose 
from range from “péssima” (“very poor”; one 
point) to “ótima” (“excellent”; seven points). The 
maximum total score on the questionnaire is 100. 
Regarding the functional scales and the global 
health and quality of life scale, higher scores are 
related to a better quality of life; however, for 
the symptom scales, higher scores correspond 
to a greater degree of the given symptom and, 
consequently, to a worse quality of life.(12)
Figure 1 - Schematic diagram of the assessment 
protocol used in the two visits. EORTC 
QLQ-C30+QLQ-LC13: 30-item European Organization 
for Research and Treatment of Cancer Core Quality 
of Life Questionnaire + 13-item Quality of Life 
Questionnaire Lung Cancer.
Table 1 - Characteristics of the 30 study 
participants.
Variablea Result
Age, years 62.0 ± 10.4
Male gender, n (%) 23 (73.7)
Smoking history, n (%)
Former smoker 27 (90)
Nonsmoker 3 (10)
Smoking history, pack-years 52.5 ± 33.4
Spirometry results
FEV1, % of predicted 75.0 ± 19.1
FVC, % do predicted 86.7 ± 13.1
FEV1 /FVC, % 71.8 ± 12.2
Histological type, n (%)
Adenocarcinoma 14 (46.7)
SCC 9 (30)
SCLC 2 (6.7)
Other 5 (16.7)
Karnofsky scale 93.2 ± 9.9
Staging, n (%)
I or II 14 (46.7)
III 13 (43.3)
IV 3 (10)
MMSE 27.9 ± 1.9
Level of education, n (%)
4 years of schooling 9 (30)
8 years of schooling 9 (30)
11 years of schooling 10 (33)
15 or more years of schooling 2 (6.7)
SCC: squamous cell carcinoma; SCLC: small cell lung 
cancer; and MMSE: Mini-Mental State Examination. 
aValues expressed as mean ± SD, except where otherwise 
indicated.
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regimen used by the patients remained unaltered 
during the 15-day interval between the two 
administrations of the questionnaires.
The mean scores on each scale of the EORTC 
QLQ-C30+QLQ-LC13 in the two visits are shown 
in Table 2.
Excellent intraobserver reproducibility was 
found for all EORTC QLQ-C30+QLQ-LC13 scores 
(Table 2). All ICCs presented p < 0.01.
Kappa reliability coefficients and p values 
were calculated individually for each question 
the questionnaire. The time required to complete 
the questionnaire was recorded for both visits.
For the purposes of the statistical analysis, 
the variables are expressed as means and 
standard deviations. The intraclass correlation 
coefficient (ICC) was calculated to assess the 
reproducibility of the questionnaire, whereas 
the kappa reliability coefficient was calculated 
to assess the reproducibility of each question. 
To compare two groups, we used the chi-square 
test for categorical variables, the Student’s 
t-test for parametric continuous variables, 
and the Mann-Whitney test for nonparametric 
continuous variables. We used ANOVA, followed 
by the Bonferroni test for multiple comparisons, 
to compare three or more different subsamples 
of patients, separated by categorical variables, 
with the purpose of determining whether 
the subsamples showed similar distribution. 
Spearman’s correlation coefficient was used 
for testing correlations between the spirometric 
variables and the questionnaire scores. Statistical 
analyses were performed with the aid of the 
Statistical Package for the Social Sciences, 
version 13.0 (SPSS Inc., Chicago, IL, USA). All 
hypothesis tests were two-tailed, and the level 
of significance was set at 5%.
Results
The principal characteristics of the 30 
patients who completed the study are shown 
in Table 1. Of the patients studied, 63.3% were 
over 60 years of age.
There were no statistically significant 
differences between the genders in terms of age, 
Karnofsky scale score, spirometry results, MMSE 
score, staging, or histological type.
Of the three patients who had never smoked, 
only one had a history of passive smoking. 
Smoking predominated in the male gender 
(p = 0.04). There was a statistically significant 
difference between the genders in terms of mean 
smoking history, which was greater in men than 
in women (53.2 ± 31.6 vs. 29.6 ± 25.5 pack-
years; p = 0.02).
Of the study participants, 8 (26.7%) were 
diagnosed with COPD, in accordance with the 
Global Initiative for Chronic Obstructive Lung 
Disease guidelines.(24)
All patients met the stability criteria, there 
being no significant clinical changes, according 
to the medical evaluation. The drug treatment 
Table 2 - Mean scores on the scales and single 
items of the 30-item European Organization for 
Research and Treatment of Cancer Core Quality of 
Life Questionnaire, in conjunction with the 13-item 
Quality of Life Questionnaire Lung Cancer, obtained in 
the two visits (15 days apart), as well as the respective 
intraclass correlation coefficients.
Scale or item Visit 
1
Visit 
2
ICC
EORTC QLQ-C30
Global health and quality of life 70.1 68.3 0.91
Physical functioning 74.1 13.8 0.92
Role functioning 75.6 81.7 0.83
Emotional functioning 71.7 76.1 0.80
Cognitive functioning 76.1 81.1 0.88
Social functioning 86.1 90.0 0.84
Fatigue 19.6 25.2 0.91
Nausea and vomiting 5.0 6.1 0.79
Pain 20.0 22.8 0.82
Dyspnea 31.1 30.0 0.80
Insomnia 25.6 16.7 0.68
Appetite loss 12.2 14.4 0.81
Constipation 13.3 17.8 0.64
Diarrhea 4.0 4.0 1.00
Financial difficulties 22.2 25.6 0.77
QLQ-LC13
Dyspnea 27.8 27.0 0.95
Cough 42.2 53.3 0.82
Hemoptysis 5.6 5.6 0.85
Mucositis 7.8 4.4 0.81
Dysphagia 11.1 11.1 0.79
Peripheral neuropathy 15.6 18.9 0.84
Alopecia 11.1 5.6 0.65
Chest pain 17.8 15.6 0.95
Arm/shoulder pain 21.1 18.9 0.95
Pain elsewhere 21.1 26.7 0.82
ICC: intraclass correlation coefficient; EORTC QLQ-C30: 
30-item European Organization for Research and 
Treatment of Cancer Core Quality of Life Questionnaire; 
and QLQ-LC13: 13-item Quality of Life Questionnaire 
Lung Cancer.
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in several reproducibility and cross-cultural 
adaptation studies involving patients with lung 
cancer.
In both visits, we registered the time 
required for each patient to complete the 
questionnaire. For the time required to complete 
the questionnaire, the means, medians, standard 
deviations, and ranges are shown in Table 4. 
There was a statistically significant difference, 
as determined by the Student’s t-test, between 
the first and second visits in terms of the times 
required to complete the three instruments 
used.
The patients responded to a number of 
questions about the difficulties in completing 
the EORTC QLQ-C30+QLQ-LC13. Regarding 
length, 94% found it appropriate, 2% found 
it short, and 8% found it long. Regarding 
difficulty, 92% stated that the instrument was 
easy to understand and 8% were of the opinion 
that some questions were confusing. Regarding 
the terms used in the questionnaire, 92% of 
the patients did not know the meaning of the 
word “obstipado” (“constipated”; question 16), 
which was explained as having “intestino preso” 
(“intestinal obstruction”). Another term that 
caused difficulties, in 16% of the sample, was 
on the EORTC QLQ-C30+QLQ-LC13 in the first 
visit and compared with those calculated in the 
second visit, with the purpose of determining 
the reproducibility of the questions after 15 
days of clinical stability. The kappa reliability 
coefficients were lower than 0.4 for questions 12, 
16, 18, 22, 26, 27, and 43b. It was not possible 
to calculate the coefficients for questions 5, 13, 
14, 15, 17, 19, 20, 21, 23, 30, 32, 36, 37, or 38. 
The remaining questions showed a moderate to 
good level of concordance.
Spearman’s correlation coefficient revealed 
no correlation between spirometric variables 
and the scores on the scales of the questionnaire 
studied.
In the present study, the mean scores on the 
global health and quality of life scale and on the 
social functioning scale of the EORTC QLQ-C30 
were above the reference values; regarding the 
symptom scales, the mean scores on the fatigue 
scale were below the reference values, whereas, 
on the pain and nausea/vomiting scales, they 
were similar to the reference values.(14) The mean 
scores on all scales of the QLQ-LC13 were similar 
to the reference values.(14) Table 3 shows the 
reference values and the mean scores reported 
for the EORTC QLQ-C30+QLQ-LC13 scales 
Table 3 - Mean scores on the scales of the 30-item European Organization for Research and Treatment of 
Cancer Core Quality of Life Questionnaire reported in several reproducibility and cross-cultural adaptation 
studies involving patients with lung cancer.
Study GHQoL PF RF EF CF SF FA NV Pain DY
Present study 70.1 74.1 75.6 71.7 76.1 86.1 19.6 5.0 20.0 31.1
Scott et al.(14)a 56.6 71.9 61.5 68.9 82.3 71.3 41.1 10.8 29.7 37.9
Wan et al.(20) 56.3 72.3 52.7 64.9 68.3 50.7 40.9 21.3 39.7 31.0
Nickalsson & Bergman(1) 50.1 52.9 46.6 72.6 77.2 65.2 52.6 14.4 34.2 46.4
Guzelant et al.(17) 56.9 55.5 74.0 74.9 80.2 70.1 46.8 17.0 37.8 30.2
Nowak et al.(25) 55.0 90.0 57.0 76.0 84.0 67.0 42.0 7.0 38.0 39.0
Chie et al.(16) 63.2 72.2 74.7 75.0 78.8 76.7 34.3 5.6 19.4 24.1
Schwarz & Hinz(19) 70.8 90.1 88.0 78.7 91.2 91.0 17.1 2.8 15.4 8.1
Apolone et al.(15) 70.2 78.1 83.1 76.1 80.3 91.1 22.0 3.4 18.5 -
Kobayashi et al.(18) 56.7 65.8 57.3 70.0 83.6 77.3 39.4 6.7 29.3 41.0
GHQoL: global health and quality of life; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: 
cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; and DY: dyspnea. aReference values.
Table 4 - Time (in min) required to complete the 30-item European Organization for Research and Treatment 
of Cancer Core Quality of Life Questionnaire in conjunction with the 13-item Quality of Life Questionnaire 
Lung Cancer at the two time points (first and second visits).
Time point Mean Median SD Range p*
First visit 9.0 8.0 3.2 5-18 < 0.001
Second visit 8.3 7.5 4.1 3-24
*Student’s t-test.
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The ICC values for most scales of the EORTC 
QLQ-C30+QLQ-LC13 were higher than 0.75, 
except for the insomnia, constipation, and 
alopecia scales. One possible reason for lower 
correlations on these scales is the fact that, in 
our sample, there was a predominance of elderly 
individuals (63.3% were over 60 years of age), 
in whom these symptoms are more unstable 
and more likely to change; our findings are in 
agreement with those reported in the validation 
study of the Chinese version of the EORTC 
QLQ-C30+QLQ-LC13.(20) In other words, low 
ICCs are related to scales measuring symptoms 
that are vulnerable to changes in perception 
over short periods of time.
Therefore, we can state that the Brazilian 
Portuguese-language version of the EORTC 
QLQ-C30+QLQ-LC13 showed good repro-
ducibility in this sample of patients. Similarly, 
we found good reproducibility, as measured by 
the kappa coefficient, for most questions.
In the present study, the EORTC 
QLQ-C30+QLQ-LC13 did not correlate with 
disease stage, although some studies have 
demonstrated such an association.(1,26) This might 
be due to the inhomogeneous distribution of our 
sample, in which most patients had early-stage 
disease (46.7% had stage I or II disease) and were 
under post-treatment follow-up (76.7%), at 
which point symptoms are much less common. 
It is known that the prevalence of uncontrolled 
symptoms, especially fatigue, dyspnea, pain, and 
anorexia, is higher in patients with progressive 
disease.(26)
Regarding pulmonary function, patients with 
reduced FEV1 are generally expected to have 
worse functional scores and more symptoms, 
especially dyspnea.(1) However, studies of cancer 
patients, such as those assessing the quality of 
life of long-term, non-small cell lung cancer 
survivors,(27,28) have reported no correlations 
between altered pulmonary function and quality 
of life.
In the present study, the mean FEV1 was 75% 
of predicted, and, as in the studies mentioned 
above, the pulmonary function test parameters 
(FVC, FEV1, FEV1/FVC) did not correlate with 
the quality of life scores. This might be related 
to the limited ability of physiological tests to 
explain the variability in individual symptom 
perception.(29) In addition, there was a very 
small number of patients with FEV1 below 50% 
found in question 10: “Você precisou repousar?” 
(Did you need to rest?) “Repousar” (literally, 
“repose”), which is the more formal term in 
Portuguese, was explained as “descansar” (“rest”). 
In the QLQ-LC13, question 33, “Sentiu falta de 
ar enquanto repousava?” (Were you short of 
breath while resting?), caused difficulties in 12% 
of the sample. “Repousava” (literally, “reposed”) 
was explained as “descansava” (“rested”).
Discussion
The objective of this study was to assess, in a 
population of patients in Brazil, the reproducibility 
of the Brazilian Portuguese-language version 
of the EORTC QLQ-C30+QLQ-LC13. The 
questionnaire showed excellent reproducibility 
when administered at two time points, 15 days 
apart, to a population of patients with lung 
cancer.
The EORTC QLQ-C30+QLQ-LC13 is a widely 
used instrument to assess the quality of life of 
patients with lung cancer and has undergone 
cross-cultural validation for use in many 
countries.(1,15-20,25) In general, the patients in 
the present study had functional and symptom 
scale scores that were similar to the reference 
values established by the EORTC quality of 
life research group. However, the analysis of 
the findings of studies of this questionnaire 
conducted in other countries shows that 
there is great variability.(1,15-20,25) Many factors 
can contribute to this variability. One is the 
existence of significant cultural differences 
between countries, differences that influence 
the conceptualization of and the reaction to 
various measurement instruments. There are 
substantial differences between countries in 
terms of scores on many scales, especially those 
related to symptom perception.(17,19)
Reproducibility was assessed by the test-
retest method. The reproducibility values for 
the EORTC QLQ-C30+QLQ-LC13 found in 
the present study ranged from 0.64 to 1.00 
and are very similar to the values reported in 
previous validation studies of other language 
versions of this instrument. The variation in 
ICC was 0.46-0.85 for the Taiwan Chinese 
version,(25) 0.32-0.80 for the Chinese version,(20) 
0.58-0.90 for the Italian version,(15) 0.70-0.94 
for the Turkey version,(17) and 0.63-0.90 for the 
Japanese version.(18)
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We conclude that the reproducibility of the 
Brazilian Portuguese-language version of the 
EORTC QLQ-C30+QLQ-LC13 is very similar to 
that of the original version. In addition, this 
Brazilian Portuguese-language version is easy 
for patients to use and understand, requiring 
just a few minutes for completion.
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